Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation by Correll, C. U. et al.
Journal Articles 
2019 
Relationship between the timing of relapse and plasma drug 
levels following discontinuation of cariprazine treatment in 
patients with schizophrenia: indirect comparison with other 
second-generation antipsychotics after treatment discontinuation 
C. U. Correll 
Zucker School of Medicine at Hofstra/Northwell, ccorrell@northwell.edu 
R. Jain 
J. M. Meyer 
A. Periclou 
T. Carrothers 
See next page for additional authors 
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles 
 Part of the Psychiatry Commons 
Recommended Citation 
Correll CU, Jain R, Meyer JM, Periclou A, Carrothers T, Barabassy A, Patel M, Earley W. Relationship 
between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment 
in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after 
treatment discontinuation. . 2019 Jan 01; 15():Article 5806 [ p.]. Available from: 
https://academicworks.medicine.hofstra.edu/articles/5806. Free full text article. 
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic 
Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara 
Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu. 
Authors 
C. U. Correll, R. Jain, J. M. Meyer, A. Periclou, T. Carrothers, A. Barabassy, M. Patel, and W. Earley 
This article is available at Donald and Barbara Zucker School of Medicine Academic Works: 
https://academicworks.medicine.hofstra.edu/articles/5806 
OR I G I N A L R E S E A R C H
Relationship between the timing of relapse and
plasma drug levels following discontinuation of
cariprazine treatment in patients with schizophrenia:
indirect comparison with other second-generation
antipsychotics after treatment discontinuation
This article was published in the following Dove Press journal:
Neuropsychiatric Disease and Treatment
Christoph U Correll1–3
Rakesh Jain4
Jonathan M Meyer5
Antonia Periclou6
Timothy Carrothers6
Ágota Barabássy7
Mehul Patel8
Willie Earley9
1Department of Psychiatry, Northwell
Health, The Zucker Hillside Hospital,
Glen Oaks, NY, USA; 2Hofstra Northwell
School of Medicine, Department of
Psychiatry and Molecular Medicine,
Hempstead, NY, USA; 3Charité
Universitätsmedizin, Department of
Child and Adolescent Psychiatry, Berlin,
Germany; 4Texas Tech University School
of Medicine – Permian Basin, Department
of Psychiatry, Midland, TX, USA;
5University of California, San Diego
School of Medicine, Department of
Psychiatry, La Jolla, CA, USA; 6Allergan,
Department of Clinical Pharmacology,
Madison, NJ, USA; 7Department of
Medical Affairs, Gedeon Richter Plc,
Budapest, Hungary; 8Department of
Medical Affairs, Allergan, Madison, NJ,
USA; 9Department of Clinical
Development, Allergan, Madison,
NJ, USA
Objective: To explore the timing of relapse following drug discontinuation and its relation-
ship to estimated plasma levels and elimination half-life by comparing data from a randomized,
placebo-controlled discontinuation study of cariprazine with those from similarly designed and
conducted randomized control trials of other oral atypical antipsychotics (AAPs).
Methods: Data from a long-term, randomized, double-blind, placebo-controlled relapse
prevention study in participants with schizophrenia (NCT01412060) were analyzed.
Similarly designed, published studies of other AAPs were used for comparison. Time to
drug-placebo relapse separation and relapse rates were estimated from Kaplan–Meier curves
and evaluated descriptively. Separation was deﬁned as a sustained difference of ≥5%
incidence of relapse between the AAP and placebo curves.
Results: The Kaplan–Meier curve for cariprazine showed a time to drug-placebo relapse
separation at 6–7 weeks after randomization, compared to the Kaplan–Meier curves for the
other AAPs, which showed earlier separation at 1–4 weeks. The placebo relapse rates at 4
weeks after randomization were 5% for cariprazine and 8–34% for other AAPs. Geometric
mean values of model-predicted plasma concentrations for total active cariprazine moieties
(sum of cariprazine, desmethyl-cariprazine, and didesmethyl-cariprazine) were 20.0 and 6.1
nM at 2 and 4 weeks after discontinuation, respectively. Elimination half-lives of other AAPs
and their active metabolites (<4 days) suggest that plasma concentrations would be low or
negligible at 2–4 weeks after last dose.
Conclusion: Discontinuation of cariprazine treatment appeared to be associated with a
delayed incidence of relapse compared with other AAPs, which may be due to the longer
half-life of cariprazine and its active metabolites.
Keywords: cariprazine, schizophrenia, half-life, occupancy
Introduction
Schizophrenia is a severe, chronic, and heterogeneous disorder that has a profound
impact on the health, social, and economic well-being of patients, families, care-
givers, and society.1,2 Relapse prevention is critical for improving long-term out-
comes in patients with schizophrenia.3 Randomized, placebo-controlled, double-blind
trials have demonstrated that continued antipsychotic treatment was signiﬁcantly
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more effective than drug discontinuation for relapse preven-
tion (number needed to treat [NNT]=3–5).3 However, par-
tial adherence and nonadherence are key threats to
symptomatic stability and functional achievements,4 and
these rates have been reported to be as high as 50%,
which can limit the efﬁcacy of pharmacotherapy.5,6
Factors contributing to partial adherence and nonadherence
include patient knowledge, attitudes toward their illness and
the medication, and past experiences with their illness and
its treatment.7 Furthermore, the medical cost of partial
adherence and nonadherence is estimated to be approxi-
mately 40% of health care spending for schizophrenia.8
Long-acting injectable antipsychotics (LAIs) have
shown superiority over oral antipsychotics in preventing
hospitalization in real-world mirror-image9 and cohort10
studies. Since pharmacologic characteristics of LAIs and
oral antipsychotics are equivalent, it is believed that the
superiority of LAIs in these studies is due to assured
medication delivery, as nonadherence is apparent upon
missing an injection, and LAIs have substantially longer
half-lives compared with oral agents.11 Supporting the
concept that the half-life of pharmacotherapy may be
important in preventing relapse, a study comparing the
effect of oral versus LAI formulations of paliperidone
found that patients who withdrew from treatment remained
relapse-free longer if they had been treated with an LAI
versus oral formulation.12 Despite the potential advantages
of LAIs, oral antipsychotics are considered to be the ﬁrst-
line treatment and are more commonly prescribed than
LAIs. This may be due to negative attitudes toward LAIs
(eg, side effects, costs) and clinicians primarily prescribing
LAIs to patients with chronic schizophrenia and a history
of partial adherence or nonadherence and/or multiple
relapses.13,14 It has also been hypothesized that oral atypi-
cal antipsychotics with longer half-lives, in a manner
similar to LAIs, may be able to bridge gaps in appropriate
medication intake by providing prolonged drug exposure
during periods of decreased adherence.15
Cariprazine, an oral dopamine D3-preferring D3/D2
receptor partial agonist, serotonin 5-HT1A receptor partial
agonist, and 5-HT2A receptor antagonist,
16 is approved for
the treatment of adults with schizophrenia (US and
Europe) and adults with manic, mixed, or depressive epi-
sodes of bipolar I disorder (US). Cariprazine forms two
major metabolites, desmethyl-cariprazine (DCAR) and
didesmethyl-cariprazine (DDCAR), which are pharmaco-
logically equipotent to and have relatively similar in vitro
binding proﬁles compared with cariprazine.17,18 Half-lives
based on time to reach steady state are 2–4 days for
cariprazine, 1–2 days for DCAR, and 1–3 weeks for
DDCAR; the effective half-life of total CAR (molar sum
of cariprazine, DCAR, and DDCAR) is approximately 1
week.17 At steady state, the most prominent moiety is
DDCAR, distantly followed by cariprazine and then
DCAR.
In contrast to cariprazine and its active metabolites, the
half-lives of all other oral antipsychotics are considerably
shorter, in the range of 7–91 hrs (eg, aripiprazole, asena-
pine, brexpiprazole, iloperidone, lurasidone, olanzapine,
paliperidone, quetiapine, ziprasidone);15 the half-lives of
their active metabolites are on the same order of magni-
tude as the parent drug. An exception is risperidone, which
has a half-life of 3 hrs, whereas its active metabolite, 9-OH
risperidone (paliperidone), has an approximate half-life of
25 hrs,19 which is consistent with most other once-daily
oral antipsychotics.
The overall objective of this post hoc, exploratory
study was to investigate if there could be a connection
between the timing of relapse following drug discontinua-
tion and estimated plasma levels (and/or elimination half-
life) by comparing data from a randomized, placebo-con-
trolled discontinuation study of cariprazine with those
from similarly designed and conducted randomized, con-
trolled trials of other oral atypical antipsychotics.
Methods
Cariprazine relapse prevention study
design
Data from a long-term, randomized, double-blind, ﬁxed-
dose, placebo-controlled relapse prevention study in parti-
cipants with schizophrenia (NCT01412060) were ana-
lyzed; detailed methods for this study are published
elsewhere.20 Brieﬂy, participants stabilized with caripra-
zine during a 20-week open-label phase were randomized
(1:1) to continue cariprazine (3, 6, or 9 mg/d) or switch to
placebo for up to 72 weeks of double-blind treatment. In
order to continue to double-blind treatment, participants
were required to meet the following stabilization criteria:
Positive and Negative Syndrome Scale (PANSS)21 total
score ≤60; decrease from baseline ≥20% in PANSS total
score; Clinical Global Impressions-Severity of Illness
(CGI-S)22 score ≤4; score ≤4 on each of the 7 PANSS
items (delusions, conceptual disorganization, hallucinatory
behavior, suspiciousness/persecution, hostility, uncoopera-
tiveness, and poor impulse control); and no signiﬁcant
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tolerability issues (investigator judged). The primary out-
come for the relapse prevention study was time to relapse
during double-blind treatment. The P-value was based on
the log-rank test; HR and 95% CI were based on Cox
proportional hazards regression model, with treatment
group as an explanatory variable.
Relapse was deﬁned by objective rating scale criteria
and subjective clinical measures. Participants were
deemed as relapsed if they met any of the following rating
scale criteria: increase ≥30% in PANSS total score for
participants who scored ≥50 at randomization or increase
≥10 in PANSS total score for participants who scored <50
at randomization; score >4 on any of the 7 PANSS items
(deﬁned above); CGI-S score ≥2 point increase from ran-
domization. Relapse was also judged to occur if, in the
investigator’s opinion, the participant was hospitalized due
to worsening of schizophrenia; exhibited deliberate self-
injury or aggressive/violent behavior; or had clinically
signiﬁcant suicidal/homicidal ideation.
This study was conducted in compliance with the
International Conference on Harmonisation Guidances on
General Considerations for Clinical Trials and Good
Clinical Practice and the Declaration of Helsinki. This
study was also approved by institutional review boards or
ethics committees and government agencies (Table S1). All
participants provided written informed consent after receiv-
ing a complete description of the studies.
Relapse prevention study designs for the
other oral atypical antipsychotics
Data from published, similarly designed relapse preven-
tion studies of other oral antipsychotics23–29 were used for
comparison. In these studies, the primary outcome mea-
sure was time from randomization to relapse or impending
relapse analyzed using standard statistical methods (eg,
log-rank test); relapse and stability criteria were deﬁned
similarly to the cariprazine study (Table S2) and partici-
pants were required to meet stabilization criteria before
proceeding to the next study phase (eg, stabilization to
randomized). Across studies, length of stabilization phase
ranged from 8 to 36 weeks, and double-blind, randomized
phase was placebo-controlled and ranged from 16 to 52
weeks; however, due to the limited number of studies
available, these factors could not be rigorously evaluated.
Two placebo-controlled, discontinuation studies (aripipra-
zole and ziprasidone)30,31 were excluded from these ana-
lyses because the studies did not include a stabilization
phase on the tested antipsychotic; rather, the enrolled
participants had been stabilized on any antipsychotic and
were then switched to either aripiprazole or ziprasidone, or
to placebo.
Relapse analyses
Kaplan-Meier (K-M) curves from published relapse preven-
tion studies of oral antipsychotics were used to estimate the
time to curve separation between drug and placebo relapse
rates. Separation was deﬁned as a sustained difference of ≥5%
incidence of relapse between drug and placebo curves; the 5%
cutoff was selected because this threshold was roughly the
point at which participants being treated with the drug gener-
ally had a signiﬁcantly lower incidence of relapse compared
with those being treated with placebo. A sensitivity analysis
using a 10% cutoff, which corresponds to NNT≤10, was also
performed to provide a threshold of established clinical
relevance.32 In addition, a post hoc analysis of the cariprazine
study was conducted to evaluate the time to curve separation
in the subset of participants who were stabilized on 3–6 mg/d
cariprazine (doses within the US Food and Drug
Administration [FDA] and European Medicines Agency
[EMA] recommended dose range).
Plasma concentrations of total CAR were obtained from
participants who were randomized to placebo in the caripra-
zine study by using individual-level predictions derived from
population pharmacokinetic models.33 Elimination half-lives
of oral antipsychotics and their active metabolites, if avail-
able, were obtained from the prescribing information of each
drug; these values were used to estimate plasma concentra-
tions after drug discontinuation. The proportions of each
active moiety at steady state (relative to total active moieties)
were calculated using mean trough plasma or serum
concentrations,34–38 but if this information was not available,
then proportions were obtained from the literature or the
drug’s prescribing information. Study characteristics such
as stability criteria, length of open-label stabilization phase,
and discontinuation protocol were evaluated descriptively for
between-study differences.
Analyses compared the time to drug-placebo relapse
separation of 5% and 10%; differences in time to drug-
placebo relapse separation and placebo relapse rates at 4
weeks after randomization between each oral antipsychotic
and their respective placebo group were compared across
drugs descriptively. The time to drug-placebo relapse
separation was also compared with the time at which
PANSS total scores separated between drug and placebo
(if information was published). The potential relationship
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between delayed relapse (eg, time to drug-placebo relapse
separation and placebo relapse rates) and weighted elim-
ination half-life was evaluated by visual inspection.
Weighted elimination half-life is the summation of each
drug and, if applicable, the active metabolite’s elimination
half-life multiplied by its proportion at steady state relative
to total active moieties; for ranges, the median was used. A
sensitivity analysis was also performed using the longest
reported elimination half-life or elimination half-life of the
most prominent moiety at steady state of each drug.
Statistical analysis could not be performed to evaluate
between-study differences due to the limited number of
available studies.
Results
This analysis included eight published placebo-controlled
relapse prevention studies of oral atypical antipsychotics
that had an open-label stabilization phase (8–36 weeks); a
summary of these studies is presented in Table 1. All studies
required participants to meet stability criteria prior to con-
tinuing to the randomized, double-blind phase (Table 1,
Table S2). Five studies23,25–28 required participants to meet
stability criteria for >8 continuous weeks; the other three
studies20,24,29 required participants to meet stability criteria
at prespeciﬁed time points. Only one study24 tapered discon-
tinuation to placebo; all others were assumed to have used an
abrupt discontinuation protocol.
Cariprazine treatment (3–9 mg/d) was associated with a
signiﬁcantly delayed time to relapse compared with placebo
(P=0.0039, HR [95% CI]=0.52 [0.33, 0.82]).39 An analysis
was also performed to evaluate the time to relapse in a sub-
group of participants that received doses of cariprazine within
the FDA- and EMA-recommended range (1.5–6 mg/d).
Treatment with cariprazine doses within this range (ie, 3–6
mg/d) was also associated with a signiﬁcantly delayed time to
relapse compared with the corresponding placebo group (ie,
participants that were stabilized on cariprazine 3–6 mg/d dur-
ing the open-label phase; P=0.026, HR [95% CI]=0.49 [0.25,
0.93]). In all studies of other oral antipsychotics, treatment
with drug compared with placebo was also associated with a
signiﬁcantly delayed time to relapse or impending relapse
(P<0.05 for all).23–29
The K-M curve for cariprazine treatment (3–9 mg/d)
showed a time to drug-placebo relapse separation at
Table 1 Relapse prevention study characteristics
Study Stabilization Stability criteriab Number
of DB patients
DB length (weeks)
Design Length (weeks)a
Asenapine27 OL 26 26 weeks continuous ASE=194
PBO=192
26
Brexpiprazole23 SB 12–40 12 weeks continuous BRX=97
PBO=105
<52c
Cariprazine20 OL 20 Meet at weeks 8 and 20 CAR=101
PBO=99
26–72
Iloperidone28 OL 15–25 12 weeks continuous ILO=153
PBO=150
<26c
Lurasidone26 OL 12–24 12 weeks continuous LUR=144
PBO=141
28
Olanzapine25 OL 8–14 8 weeks continuous OLZ=224
PBO=102
<30c
Paliperidone ER29 OL 14 Meet at weeks 8 and 14e PAL=105
PBO=102
16–40c
Quetiapine XR24,d OL 16 Meet at weeks 8 and 16 QTP=94
PBO=103
≤39c
Notes: aLength includes cross-titration, run-in, and stabilization periods, if applicable, and ranges indicate that patients could move to randomization phase once stability
criteria were met; bdetails on stability criteria are provided in Table S1; cvariable length is due to positive interim results and subsequent early study termination; dQTP XR
was the only study that had a tapered discontinuation protocol (4-day cross titration); estability criteria obtained from https://clinicaltrials.gov/ct2/show/NCT00086320.
Abbreviations: ASE, asenapine; BRX, brexpiprazole; CAR, cariprazine; DB, double-blind; ER or XR, extended release; ILO, iloperidone; LUR, lurasidone; OL, open-label;
OLZ, olanzapine; PAL, paliperidone; PBO, placebo; QTP, quetiapine; SB, single-blind.
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6.6 weeks after randomization (Figure 1A); this correlated
with time to separation of PANSS total score change between
cariprazine and placebo (Figure S1). For participants stabilized
in the recommended 3–6 mg/d dose range, the K-M curve
showed that time to drug-placebo relapse separation occurred
even later, at 8.3 weeks, when compared with its correspond-
ing placebo group (Figure 1B).
K-M curves from studies of other oral antipsychotics
showed earlier separation between drug and placebo, ran-
ging between 1 and 4 weeks (Table 2). Two of these
studies published by-week PANSS total score data; in
those studies, time to drug-placebo relapse separation
also coincided with the between-group separation of
PANSS total score change (lurasidone: ~3 weeks vs 4
weeks, respectively; paliperidone ER: 1.6 weeks vs 1
week, respectively).26,29
In the cariprazine study, overall placebo relapse rate at
week 4 was estimated to be 5%; the estimated placebo relapse
rates for the other oral antipsychotics were higher, ranging
from 8% to 34% at 4 weeks after last dose (Table 2).
Brexpiprazole, with the second longest half-life after caripra-
zine, had the second lowest placebo relapse rate and second
longest time to drug-placebo relapse separation. The remain-
der of the oral antipsychotics all had half-lives of approxi-
mately 1 day or less; correspondingly, these compounds had
the highest placebo relapse rates at week 4 and shortest time to
drug-placebo relapse separation following treatment
discontinuation.
Placebo relapse rate and time to drug-placebo relapse
separation appeared to be correlated with elimination half-
life (Table 2); a graphical representation plotting relapse out-
comes versus weighted elimination half-life is shown in Figure
2. A similar trend was seen for time to drug-placebo separation
with clinically relevant separation deﬁned as ≥10% sustained
difference (equivalent to an NNT=10) compared with separa-
tion deﬁned as ≥5% sustained (Figure 2B-C; Table 2).
Analyses were performed using the longest drug or metabolite
elimination half-life, as well as using median elimination half-
life of the most prominent moiety instead of weighted half-
life; results were similar regardless of half-life calculation
method (data not shown).
Geometric mean values of model-predicted plasma con-
centrations for total CAR were 20.0 and 6.1 nM at 2 and 4
weeks after last cariprazine dose, respectively (Figure 3).
Based on published EC50 estimates for D2 and D3 receptor
occupancy by total CAR, which are 13.0 and 3.8 nM,
respectively,40 D2 and D3 receptors are predicted to remain
occupied at 2 and 4 weeks after last cariprazine dose.
Geometric mean values of model-predicted plasma concentra-
tions for DDCAR, which is the most prominent moiety at
steady state, were 18.5 and 5.5 nM at 2 and 4 weeks after
last cariprazine dose, respectively. Elimination half-lives of
other oral antipsychotics and their active metabolites (Table 2)
suggest that plasma concentrations and D2 and D3 receptor
occupancy for those compounds would be low or negligible at
2 and 4 weeks after last dose.
Discussion
This analysis examined the relationship between the trajec-
tories of the incidence of relapse and the plasma concentra-
tions of oral antipsychotics in participants with
schizophrenia after drug discontinuation (eg, randomization
to double-blind placebo). In all of the relapse prevention
studies that were included in this post hoc, exploratory
study, treatment with oral antipsychotics was signiﬁcantly
superior versus placebo at delaying schizophrenia relapse or
Figure 1 Cumulative rate of relapse.
Notes: aKaplan–Meier curves for time to relapse in the ﬁnal intent-to-treat (ITT),
randomized population during the double-blind period for cariprazine 3–9 mg/d
versus the overall placebo group (A) and for cariprazine 3–6 mg/d versus its
corresponding placebo group (B); bthick vertical bar represents 5% incidence of
relapse and indicates the time to drug-placebo relapse separation. Panel A is
adapted from © 2019 Allergan. Used with permission.
Dovepress Correll et al
Neuropsychiatric Disease and Treatment 2019:15 submit your manuscript | www.dovepress.com
DovePress
2541
impending relapse.20,23-29,39 This study found that there was
a delayed incidence of schizophrenia relapse following dis-
continuation of cariprazine treatment relative to disconti-
nuation of treatment with the other oral antipsychotics as
reported in separate studies. The incidence of relapse at 4
weeks following discontinuation of cariprazine treatment
(5%) was approximately 2–7 times lower than that observed
following drug discontinuation in other relapse prevention
studies (8–34%). In addition, time to separation between
cariprazine and placebo for estimated relapse incidence was
6.6 weeks compared with 1–4 weeks in the other studies.
For all oral antipsychotics, the lower placebo relapse rate at
week 4 and the longer time to drug-placebo relapse separa-
tion were associated with a longer elimination half-life.
Factors other than half-life, such as length of open-label
stabilization phase and type of drug discontinuation proto-
col, were relatively consistent across studies. These factors
do not appear to be differentiating factors for relapse rate
trajectories in the placebo group or time to drug-placebo
relapse separation following antipsychotic discontinuation;
however, due to the limited number of studies available, a
rigorous evaluation could not be performed. Although the
primary analysis in the cariprazine study included some
participants who received a cariprazine dose outside the
recommended range (9 mg/d), time to drug-placebo relapse
separation for the approved dose range of 3–6 mg/d was
even longer compared with the 3–9 mg/d dose range, sug-
gesting that the 9 mg/d dose was not a differentiating factor
for the delayed time to drug-placebo relapse separation.
Overall, relapse occurred in 49.5% of placebo- and 29.7%
of cariprazine-treated participants.39 The relapse rates at the
study endpoint on active medication in the cariprazine study
are similar to what has been reported in a meta-analysis of
relapse prevention studies in schizophrenia, which found
that antipsychotics (27%) signiﬁcantly reduced relapse
rates at 1 year versus placebo (64%);3 thus, the overall
Table 2 Placebo relapse rate, time to drug-placebo relapse separation, and elimination half-lives of drugs and major active metabolites
Drug PBO relapse at
week 4 (%)a
Time to drug-PBO
relapse separation
(weeks)a
Elimination half-life of drug and
major active metabolitesb
Proportionc at steady state of
drugs and active metabolites
5%
Separation
10%
Separation
CAR 5 6.6 12.0 CAR: 2–4 days
DCAR: 1–3 days
DDCAR: 1–3 weeksd
CAR: 23.3%
DCAR: 7.2%
DDCAR: 69.5%e
BRX 8 4.0 6.1 BRX: 91 hrs No CNS active metabolites
QTP XRf 13 2.7 3.4 QTP: 7 hrs
Norquetiapine:12 hrs
QTP: 30.3–35.7%
Norquetiapine: 64.3–69.7%g
OLZ 15 2.6 4.1 OLA: 30 hrs No CNS active metabolites
LUR 15 2.7 8.2 LUR: 18 hrs
ID-14283: 7.5–10 hrsh
LUR: 70%
ID-14283: 26%i
ASE 18 1.1 2.4 ASE: ~24 hrs No CNS active metabolites
ILO 24 1.1 3.3 ILO: 18–33 hrs
P95: 23–31 hrs
P88: 26–37 hrs
ILO: 32.5%
P95: 48%
P88: 19.5%j
PAL ERf 34 1.6 3.3 PAL ER: 23 hrs No CNS active metabolites
Notes: aEstimated from ﬁnal intent-to-treat population Kaplan–Meier curve; separation was deﬁned as a sustained difference of ≥5% or ≥10% incidence of relapse between
drug and placebo curves; belimination half-life values were obtained from the prescribing information of each drug unless otherwise speciﬁed; cproportion of drug and active
metabolites is relative to total active moieties; delimination half-lives for cariprazine, DCAR, and DDCAR are based on time to steady-state values; eproportions calculated
using model-predicted Cmin values at steady state from a population pharmacokinetic modeling study (A.P. and T.C., unpublished data, 2014);
fplease note that QTP XR and
PAL ER are sustained-release formulations; gproportions calculated using serum concentrations from Bakken et al (2011)35 and Bakken et al (2015)34 with the assumption
that steady-state pharmacokinetic parameters are similar for the IR and XR formulations as reported by Bui et al (2013);36 helimination half-life for ID-14,283 was obtained
from Citrome (2011);37 iproportions are from Meyer et al (2009)38 and based on mean serum concentrations; jproportions at steady state are from extensive metabolizers
in the prescribing information for ILO.
Abbreviations: ASE, asenapine; BRX, brexpiprazole; CAR, cariprazine; CNS, central nervous system; DCAR, desmethyl-cariprazine; DDCAR, didesmethyl-cariprazine; ER
or XR, extended release; ILO, iloperidone; LUR, lurasidone; OLZ, olanzapine; PAL, paliperidone; PBO, placebo; QTP, quetiapine.
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relapse rate also does not appear to be a differentiating
factor for the delayed relapse seen after the discontinuation
of cariprazine.
The long half-life of cariprazine is primarily due to the
presence of an active metabolite (DDCAR) with an
extended half-life (1–3 weeks) that is considerably longer
than that of the parent drug (2–4 days). In contrast, half-
lives for the active metabolites of the compared antipsy-
chotics are approximately the same as that of the parent
drug (<4 days). At steady-state and under ﬁxed-dosing
conditions, DDCAR is the most prominent moiety (Table
2).33 Based on the geometric mean values of model-pre-
dicted plasma concentrations of DDCAR and its relative
value to total CAR, the presence of DDCAR alone may be
enough to occupy D2 and D3 receptors at 2 and 4 weeks
after last dose.
Occupancy of dopamine receptors is believed to be the
main mechanism of action for antipsychotics.41,42 It is
believed that 65–80% occupancy of striatal dopamine
receptors is associated with optimal therapeutic efﬁcacy,
although an analysis of the CATIE trial found that over
half of the patients in remission had D2 occupancy levels
below 65%.43 This observation may suggest that during
maintenance treatment, lower levels of D2 occupancy may
be sufﬁcient to delay relapse and provide maintained treat-
ment beneﬁts for stabilized patients. In the cariprazine
study, predicted plasma concentrations of total CAR sug-
gest that patients who have discontinued from cariprazine
treatment may have substantial D2 occupancy at 2 weeks
after last dose and moderate D2 occupancy at 4 weeks after
last dose. Additionally, plasma concentrations of caripra-
zine indicate that D3 receptors are substantially occupied
at 2 and 4 weeks after last dose; while it is unknown what
roles D3 receptors have in relapse prevention in patients
with schizophrenia, it is believed that they may be
involved in modulating cognition, mood, reward, and
negative symptoms.42,44–46
Relapse can be decreased by uninterrupted pharmaco-
therapy,47 but in reality, most outpatients are only partially
adherent to their medication regimen.48,49 After an initial hos-
pital stay, schizophrenia and other psychotic disorders are the
leading cause of 7-day readmission and third leading cause of
30-day readmission.50 In several naturalistic studies, nonad-
herence rates in patients with schizophrenia ranged from 30%
to 60%; however, these numbers appear to drop to approxi-
mately 10% or lower in randomized clinical trials where
selected patients agreeing to take part in a research study are
monitored by health care professionals and have regular access
to health care.7 This ﬁnding indicates that better measures are
needed in real-world settings to deliver continued treatment to
patients on a regular basis. LAIs were introduced as a possible
solution; however, not all patients are willing to take an LAI,
and despite having been on the market for several years, their
usage rate among patients with schizophrenia still pales in
comparison to oral antipsychotics.13 Thus, given the evidence
seen with LAIs,9–12 oral medications that can provide the
patient with sufﬁcient coverage fromwhen they are discharged
from the hospital to the time of their ﬁrst outpatient appoint-
ment may be able to reduce rates of relapse and rehospitaliza-
tion. Half-lives of LAIs range from 4–6 days (eg, risperidone-
LAI) to 1–2 months for other LAIs (eg, aripiprazole-LAI
[30–57 days], paliperidone-LAI [24–49 days], olanzapine-
LAI [approximately 30 days]).51–55 With an effective half-
life of approximately 1 week and occupancy of dopamine
receptors for up to 4 weeks after the last dose, cariprazine
may be an example of an oral antipsychotic that can effectively
bridge gaps to provide more beneﬁcial medication coverage.
Figure 2 Drug half-life versus placebo relapse rate (A) and separation from active
drug (B-C).
Notes: aLogarithm regression ﬁts were generated to provide a visual guide;
bestimated from ﬁnal intent-to-treat population Kaplan–Meier curve; cweighted
half-life values based on elimination half-life and steady-state proportions of each
drug (and its metabolites) were used (Table 2).
Abbreviations: ASE, asenapine; BRX, brexpiprazole; CAR, cariprazine; ILO, ilo-
peridone; LUR, lurasidone; OLZ, olanzapine; PAL, paliperidone; PBO, placebo; QTP,
quetiapine.
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Results from this study need to be interpreted within its
limitations. For example, time to drug-placebo relapse
separation and placebo relapse rate were estimated from
published K-M curves since primary data were not available
for analysis. Another limitation is the lack of standardized
deﬁnition of curve separation. For this study, 5% and 10%
separation were used; however, it is possible that the results
may be affected if a different percent separation value was
used. It should also be noted that in the cariprazine study,
participants received 20 weeks of open-label cariprazine and
were at steady-state dosing by the time of randomized with-
drawal; as such, it is unclear how relapse rates would change
if cariprazine was taken on an inconsistent basis and then
abruptly discontinued. Further, the beneﬁcial property of
delayed relapse is not well understood and has not been
empirically validated. Additionally, due to differences in
study designs between the cariprazine relapse prevention
study and published studies of some oral antipsychotics,
these analyses should be interpreted cautiously and could
not include comparisons with some frequently used oral
antipsychotics (eg, aripiprazole, ziprasidone) as published
studies with a similar design were not available. Future
head-to-head, prospective, randomized clinical trials are
needed to conﬁrm the results of this post hoc, exploratory
study.
In conclusion, the delayed incidence of relapse seen
after discontinuation of cariprazine compared with other
oral atypical antipsychotics appears to be at least partially
due to the particularly long half-life of cariprazine and its
active metabolites, which is substantially longer than the
half-life of the other oral atypical antipsychotics and their
active metabolites. Results from this analysis suggest that
the long half-life of cariprazine may result in additional
protection from schizophrenia relapse in cases of partial
adherence, though prospective comparative trials are
needed to conﬁrm these results.
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Table S1 List of independent ethics committee and institutional review boards
Country Independent ethics committees/institutional review boards
USA Copernicus Group
Sharp Healthcare IRB
University of Texas - Houston Health Science Center
Ofﬁce of Research Support Committees
India Ethics Committee, Shanti Nursing Home, Society for Psychiatric Update and Research
IMS - Independent Ethics Committee
Ethical Committee Sheth VS Hospital
Institutional Ethics Committee, Ofﬁce of Research Cell, C.S.M. Medical University
Vijayawada Institute of Mental Health and Neurosciences Hospital –
Ethics Committee
Clinic Ethics Forum
DMHC Ethics Committee
Independent Ethics Committee, 57, Brahmin Mitra Mandal Society
Kanpur Medical Ethics Committee
Safe Search Independent Ethics Committee
Yash Society Ethics Committee
Ethics Committee, Radianz Healthcare and Research
Central Ethics Committee, Nitte University
Manipal University Ethics Committee, Manipal University
The Ethics Committee, R.K. Yadav Memorial Mental Health and De-addiction Hospital
Romania Academia de Stiinte Medicale, Comisia Nationala de Bioteca a Medicamentului si a Dispozitivelor Medicale
Comisia Nationala de Etica pentru Studiul Clinic al Medicamentului
Slovak Republic Eticka komisia NsP sv.Barbory Roznava a.s,
Eticka komisia pri LNsP MUDr. Ivana Stodolu Liptovsky Mikulas,
Eticka komisia Vseobecnej nemocnice Rimavska Sobota NaP
Eticka komisia Fakultnej nemocnice Trnava
Eticka komisia Univerzitnej nemocnice Ruzinov Bratislava
Eticka komisia LF UK a Univerzitnej nemocnice
Ukraine Ethics Commission at Kyiv City Clinical Psychoneurological Hospital #1
Ethics Commission of Kyiv City Psychoneurological Hospital #2
Ethics Commission of Communal Institution Lviv Regional Clinical Psychiatric Hospital
The Ethics Commission of State Medical and Preventive Institution
Central Clinical Hospital of Ukrzaliznytsia
Ethics Committee of the Kharkiv Regional Clinical Psychiatric Hospital #3
Ethics Commission at SE Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine
Ethics Commission of Communal Institution Kherson Regional Psyciatric Hospital of Kherson Regional Council
Ethics Commission at Communal Institution O.I. Yushchenko Vinnytsia Regional Psychoneurologic Hospital
Ethics Commission of Crimea Republic Institution Psychoneurological Dispensary
Ethics Commission of Communal Institution Dnipropetrovsk Clinical Psychiatric Dnipropetrovsk Regional Council
Ethics Commission at Crimea Republic Institution Clinical Psychiatric Hospital #1
Ethics Commission at City Clinical Psychoneurological Hospital #1
Ethics Commission at Communal Therapeutic and Preventative Institution “Regional Clinical Psychiatric Hospital”
Ethics Commission at Odessa Regional Medical Centre of Mental Health
Ethics Committee of Regional Psycho-Neurological Hospital #3
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Table S2 Detailed stability criteria used in the relapse prevention studies
Drug Checkpoints Stability criteria
CAR1 Meet at week 8/20 PANSS total score≤60; ≥20% decrease in PANSS total score from baseline; CGI-S≤4; score≤4 on each of the 7
PANSS items (delusion, conceptual disorganization, hallucinatory behavior, suspiciousness/persecution, hosti-
lity, uncooperativeness, and poor impulse control); no signiﬁcant tolerability issue (investigator judged)
BRX2 12 weeks continuous Outpatient status; PANSS total score≤70; score of ≤4 on each of the 4 PANSS items (conceptual disorgani-
zation, suspiciousness, hallucinatory behavior, and unusual thought content); CGI-S≤4; no current suicidal
behavior as assessed by C-SSRS; no violent or aggressive behavior resulting in injury or property damage
QTP XR3 Meet at week 8/16 On established dose; CGI-S≤4; PANSS total score≤60 at week 0 (enrollment; inclusion criteria), with no
change ≥10 points in PANSS total score from week 0 to 8 and from 0 weeks to 0 (randomization baseline)
OLZ4 8 weeks continuous Did not meet relapse criteria (an increase in any BPRS positive item to >4, and either an absolute increase
of ≥2 on that speciﬁc item or an absolute increase of ≥4 on the BPRS positive subscale [conceptual
disorganization, hallucinatory behavior, suspiciousness, unusual thought content]; hospitalization due to
positive psychotic symptoms; a priori secondary deﬁnition of relapse was a completed suicide or a serious
suicide attempt [as determined by the investigator])
LUR5 12 weeks continuous On a stable dose for 4 weeks prior to randomization; PANSS total score≤70, with PANSS item scores≤4
on all positive subscale items and “uncooperativeness” item, and a CGI-S<4. Note: two excursions
(deﬁned as 70<PANSS total score≤80 and/or a CGI-S=4 and/or PANSS positive subscale item=5) were
permitted (post-stability attainment), except during the last 4 weeks of stabilization phase.
ASN6 26 weeks continuous Did not experience loss of stability (PANSS total score increase of ≥20% increase in PANSS total score or
12 pts from baseline), or met any exclusion criteria (PANSS total score>75, CGI-S>3, score≥4 on items
[unusual thought content, conceptual disorganization, hallucinatory behavior, hostility, or uncooperative-
ness]), or ISST scores of 2 on items 7, 10, or 11
ILO7 12 weeks continuous On stable dose for at least 4 weeks prior to randomization; CGI-S≤4, ﬁve individual PANSS positive
symptoms (delusions, conceptual disorganization, hallucinatory behavior, suspiciousness/persecution, hos-
tility) and uncooperative item score≤4, PANSS total score ≤70, and not requiring any new acute treatment
service intervention
PAL ER8 Meet at week 7/8 and
9–14a
Stable dosage regimen; PANSS total score≤70; CGI-S≤4; scores≤4 for PANSS items for delusions, con-
ceptual organization, hallucinatory behavior, suspiciousness/persecution, hostility, and uncooperativeness.
Notes: aObtained from https://clinicaltrials.gov/ct2/show/NCT00086320.
Abbreviations: ASE, asenapine; BPRS, Brief Psychiatric Rating Scale; BRX, brexpiprazole; CAR, cariprazine; CGI-S, Clinical Global Impression Scale – Severity; C-SSRS,
Columbia-Suicide Severity Rating Scale; ER or XR, extended release; ILO, iloperidone; ISST, InterSePT Scale for Suicidal Thinking; LUR, lurasidone; OLZ, olanzapine; PAL,
paliperidone; PANSS, Positive and Negative Syndrome Scale; PBO, placebo; QTP, quetiapine.
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Figure S1 By-week change from baseline in PANSS total score (MMRM).
Abbreviations: LS, least squares; MMRM, mixed-effects model for repeated measures; PANSS, Positive and Negative Syndrome Scale.
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